To address this question, we investigated patients with AD and HC for their Gal-9 serum levels and rates of circulating TIM-3-positive cells, we characterized the clinical relevance of Gal-9 and TIM-3 in AD, and we explored potential mechanisms that underlie their role in the pathogenesis of AD. This evidence concerns the gene HAVCR2 and Alzheimer disease.